4 completed, 3 recruiting, 1 unknown. 8 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Recruiting 3, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow senicapoc: new trials by email Literature Review of senicapoc trials Research Report on senicapoc
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype Senicapoc, Placebo - Sickle Cell Disease, Sickle Cell Anaemia | Phase 2 | Recruiting | Biossil Inc. | 65 | 2026-11-01 | 2026-11-02 |
| Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease Senicapoc, Placebo - Pulmonary Fibrosis, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis | Phase 2 | Recruiting | Vejle Hospital | 140 | 2025-08-01 | 2026-05-07 |
| Senicapoc in Alzheimer's Disease Senicapoc, Placebo Tablet - Mild Cognitive Impairment, Alzheimer Disease | Phase 2 | Recruiting | University of California, Davis | 55 | 2022-03-18 | 2026-08-17 |
| Senicapoc and Dehydrated Stomatocytosis Senicapoc (synonyms: ICA-17043; 2,2-bis-(4-fluorophenyl)-2-phenylacetamide) - Dehydrated Hereditary Stomatocytosis | Phase 1 / Phase 2 | Completed | Boston Children's Hospital | 5 | 2021-04-15 | 2024-02-22 |
| Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency Senicapoc - ARDS, Human, COVID | Phase 2 | Unknown | University of Aarhus | 46 | 2020-04-24 | 2020-10-20 |
| Study to Assess Safety and Efficacy of Oral Senicapoc Administration on Exercise-induced Asthma senicapoc, Placebo - Exercise Induced Asthma | Phase 2 | Completed | Icagen | 69 | 2009-03-01 | 2011-07-14 |
| Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects senicapoc, Placebo - Atopic Asthma | Phase 2 | Completed | Icagen | 34 | 2008-10-01 | 2011-07-14 |
| A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia. Low Dose ICA-17043, High dose ICA-17043, Placebo - Sickle Cell Disease, Sickle Cell Anemia | Phase 2 | Completed | Icagen | 90 | 2002-02-01 | 2011-07-18 |
Anemia (2) · Anemia, Sickle Cell (2) · Inflammation (2) · Alzheimer Disease (1) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Congenital (1) · Asthma (1) · Asthma, Exercise-Induced (1) · Bronchial Spasm (1) · Cognitive Dysfunction (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Coronavirus Infections (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1)
Icagen (3) · Biossil Inc. (1) · Boston Children's Hospital (1) · University of Aarhus (1) · University of California, Davis (1) · Vejle Hospital (1)
United States (4) · Denmark (2) · United Kingdom (2) · Canada (1) · Estonia (1)
Asger Granfeldt, MD, PhD (1) · Bodil S Rasmussen, MD, PhD (1) · Carlo Brugnara, MD (1) · John Olichney, MD (1) · Jonathon Stocker, Ph.D. (1) · Kenneth I Ataga, MD (1) · Klaus T Kristiansen, MD (1) · Ole Hilberg, Proffesor (1) · Steffen Christensen, MD (1) · Tak H Lee, FRCP (1)